Financial Performance
5Y price score: 38
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 92%
US$ Per
Share
By default your notes are visible only to you.
541.0
52-week range
821.1
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
4.1 %
Dividend Yield TTM
0.5 %
Market cap $
$ 83,033
Price / Earnings TTM
19.9
Price / Book TTM
2.6
PEG TTM
2.4
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
44.2 %
29.6 %
92 %
Free cash flow per share growth
18 %
115.9 %
563.2 %
Earnings per share growth
8.2 %
35.9 %
651.4 %
Founded: 1,988
Employees: 15,158
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Jul 30, 2026)
1) Strong Financial Performance
- Regeneron reported total revenues of $4.3 billion for Q2 2026, a 17% increase YoY.
- Non-GAAP earnings per share rose 11% to $14.29, with net income reaching $1.5 billion.
- Sanofi collaboration revenue hit an all-time high of $2.2 billion, with Regeneron's share of profits growing 59% YoY.
- EYLEA HD and Libtayo contributed significantly to revenue growth, with EYLEA HD net sales at $596 million, up 52% YoY.
2) Product Highlights and Pipeline Developments
- Dupixent achieved global net sales of $6 billion, reflecting a 38% increase on a constant currency basis.
- EYLEA HD surpassed EYLEA in sales for the first time, indicating strong market adoption.
- Libtayo's sales reached nearly $500 million, a 29% increase YoY, driven by its strong position in non-small cell lung cancer.
- Upcoming milestones include FDA decisions for cemdisiran in November and ongoing advancements in the obesity and oncology pipelines.
3) Strategic Collaborations and Future Opportunities
- Regeneron is exploring further collaboration opportunities with Sanofi, particularly around Dupixent follow-on programs.
- The company remains open to external opportunities but emphasizes disciplined valuation in potential M&A activities.
- The focus on internal R&D continues, with approximately 50 active clinical programs across various therapeutic areas.
4) Operational Challenges and Market Dynamics
- EYLEA's sales are expected to decline sequentially in the low to mid-teens due to competitive pressures and ongoing conversion to EYLEA HD.
- The company is navigating regulatory complexities, particularly with the EYLEA HD prefilled syringe, which is under review.
- The competitive landscape in myasthenia gravis is intensifying, with cemdisiran set to enter a market with established therapies.
5) Guidance and Outlook
- Regeneron expects continued strong growth for Dupixent and EYLEA HD, though Dupixent's growth may moderate in the second half of 2026.
- The company is refining its financial guidance for 2026, anticipating increased Sanofi collaboration revenue following the repayment of development balances.
- The call lacked detailed forward-looking guidance on specific product launches and market strategies, which may be critical for investors.
Bottom line: Regeneron's robust Q2 performance, driven by strong sales of Dupixent and EYLEA HD, positions the company well for future growth. With a diverse pipeline and strategic collaborations, Regeneron is poised to deliver sustained value to shareholders, despite facing competitive and regulatory challenges.
Annual Reports, Presentations And IR Contacts
Go to the websiteRegeneron Pharmaceuticals — Financial Overview, Stock Price, Market Cap
Regeneron Pharmaceuticals is a company. Founded in 1988. As of August 14, 2026, the company's market capitalization is $83032641340 with a current stock price of $805.97.